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Letters
AntimicrobiAl resistAnce in 
CampylobaCter isolAtes from sporAdic 
cAses of Acute humAn gAstroenteritis in 
northern irelAnd
Editor, 
Thermophilic  campylobacters,  particularly  Campylobacter 
jejuni, continue to remain the most common cause of acute 
bacterial enteritis in Northern Ireland. Most recent confirmed 
data for 2006 recorded 937 laboratory reports for Northern 
Ireland (http://www.cdscni.org.uk/surveillance/Gastro/
Campylobacter_sp.htm),  approximating  to  53.8  cases  per 
100,000 individuals, compared to an attack rate of 86.7 and 
42.8  cases  per  100,000  individuals  for  England  & Wales 
and  the  Republic  of  Ireland,  respectively.    However,  in  a 
previous epidemiological study1, it was estimated that the 
true prevalence of this infection was approximately 10.3-fold 
higher, due to patient under-reporting.
In relation to antibiotic resistance of local campylobacters, 
we  have  continued  to  map  resistance  trends2,3  during  the 
perod 2004-2007 (n=1102) (Table I). The worrying finding 
of this study has been the marked increase in resistance to 
ciprofloxacin, rising to 31.7% in 2007, which is the highest 
level of resistance of these organisms to this agent that has ever 
been reported in Northern Ireland. Susceptibility data relating 
to ciprofloxacin resistance in local human clinical isolates 
were first reported in 1996 (9%) and this resistance rate has 
since risen steadily.  Presently, the reason(s) for this increase 
in resistance is unclear. The most likely explanation for this is 
the ingestion of campylobacters which are more resistant to 
this agent, rather than the acquisition of resistance de novo in 
the human gastrointestinal tract, epecially as these organisms 
do not form part of the ecological microflora of the human 
gut.  This  therefore  encourages  examination  of  reservoirs 
and sources where such resistant organisms may enter the 
food chain. One possibility may be consumption of imported 
poultry meat from origins outside the EU, where veterinary 
controls of the use antibiotics in animal husbandry may not be 
stringent, thus leading to the development of fluoroquinolone 
resistant isolates in chickens prior to slaughter. A previous 
report  in  20034  described  the  importation  to  Northern 
Ireland of 500 tonnes of chicken meat per week, which had a 
resistance to ciprofloxacin of 14% of isolates tested.  Similar 
studies from Belgium5 and Spain have suggested ciprofloxacin 
resistance in poultry to be 42% and 99%, respectively.
Another explanation for this rise in ciprofloxacin resistance 
in local human infections may be the acquisition  of more 
resistant  strains  outside  of  Northern  Ireland,  particularly 
relating to travel abroad. The arrival of several budget and low 
cost airlines to Northern Ireland has lead to a marked increase 
in Northern Ireland residents travelling to countries which 
have a higher endemic rate of fluoroquinolone-resistance in 
campylobacters originating from animals, as well as humans. 
In 2007, airport passenger traffic to EU destinations increased 
by 21% at Belfast International Airport, resulting in 1,490, 
775  passenger  journeys  (http://www.caa.co.uk/docs/80/
airport_data/2007Annual/Table_10_1_EU_and_Other_
Intl_Pax_Traffic_2007.pdf). Urgent attention now needs to 
be directed at this resistance issue in order to ascertain the 
origins of this marked rise in ciprofloxacin-reisitance in local 
campylobacters.
In  conclusion,  primary  care  practitioners,  specialists  in 
infectious  diseases,  microbiologists  and  epidemiologists 
need to be aware of the local increase in antibiotic resistance 
of  thermophilic  campylobacters  to  ciprofloxacin  (31.2%) 
and the relative susceptibility of local wildtype isolates to 
erythromycin (1.2%).
Acknowledgements:  This  study  was  funded  by  the  Research  & 
Development Office, Department of Health & Public Safety, Northern 
Ireland [Infectious Disease—Recognised Research Group (RRG) 
9.9]. The authors have no conflict of interest. 
John E Moore1,2*, Clinical Scientist in Clinical Microbiology,
B Cherie Millar1,  Clinical Scientist in Molecular Microbiology,
M Ann S McMahon3, Research Fellow,
David A McDowell3, Professor of Microbiology,
Paul J Rooney1, Consultant Microbiologist.
1Northern  Ireland  Public  Health  Laboratory,  Department  of 
Bacteriology,  Belfast  City  Hospital,  Belfast,  BT9  7AD,  UK, 
2School of Biomedical Science, Centre for Molecular Biosciences, 
University of Ulster, Cromore Road, Coleraine, BT52 1SA, UK,. 
3Food Microbiology Research Group, University of Ulster, Shore 
Road, Jordanstown, Newtownabbey, BT37 0QB, UK.
jemoore@niphl.dnet.co.uk
references
1.   Food Standards Agency. A report of the study of infectious 
intestinal disease in England. London: The Stationary Office; 
2000. 
2.  Moore  JE,  Crowe  M.  Heaney  N.  Crothers  E.    Antibiotic 
resistance in Campylobacter spp. isolated from human faeces 
(1980–2000) and foods (1997–2000) in Northern Ireland: an 
update. J Antimicrob Chemother  2001;48(3):455–7.
3.  Rao  D,  Rao  JR,  Crothers  E,  McMullan  R,  McDowell  D, 
McMahon A, et al. Increased erythromycin resistance in clinical 
Campylobacter in Northern Ireland--an update.  J Antimicrob 
Chemother 2005;55(3):395-6.
4.   Wilson IG. Antibiotic resistance of Campylobacter in raw retail 
chickens  and  imported  chicken  portions.  Epidemiol  Infect. 
2003;131(3):1181-6.
5.   Van Looveren M, Daube G, De Zutter L, Dumont JM, Lammens 
C,  Wijdooghe  M,  et  al.  Antimicrobial  susceptibilities  of 
Campylobacter strains isolated from food animals in Belgium.   
J Antimicrob Chemother 2001;48(2):235-40.
Table I:
Percentage of wildtype Campylobacter isolates resistant to 
three antibiotic agents over the period 2004-2007.
Year
Antibiotic 2004
(n=237)
2005
(n=297)
2006
(n=309)
2007
(n=259)
Ciprofloxacin 20.3% 18.9% 23.6% 31.7%
Erythromycin 2.5% 3.4% 1.9% 1.2%
Tetracycline 20.2% 19.5% 19.7% 22.8%